CORESTEMCHEMON Inc. (KOSDAQ:166480)
South Korea
· Delayed Price · Currency is KRW 2,785.00
-35.00 (-1.24%)
At close: Mar 6, 2026
CORESTEMCHEMON Revenue
CORESTEMCHEMON had revenue of 3.60B KRW in the quarter ending September 30, 2025, a decrease of -56.66%. This brings the company's revenue in the last twelve months to 20.13B, down -30.31% year-over-year. In the year 2024, CORESTEMCHEMON had annual revenue of 28.76B, down -14.54%.
Revenue (ttm)
20.13B
Revenue Growth
-30.31%
P/S Ratio
5.73
Revenue / Employee
559.16M
Employees
36
Market Cap
115.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.76B | -4.89B | -14.54% |
| Dec 31, 2023 | 33.66B | -12.22B | -26.64% |
| Dec 31, 2022 | 45.88B | 15.64B | 51.71% |
| Dec 31, 2021 | 30.24B | 3.88B | 14.73% |
| Dec 31, 2020 | 26.36B | 2.07B | 8.54% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIO-FD&C | 18.82B |
| NovMetaPharma | 1.30B |
| ViGenCell | 278.95M |
| IMGT Co.,Ltd. | 102.33M |
| Quratis | 2.28B |
| TegoScience | 6.15B |
| Progen | 450.00M |
| Cell Biotech | 50.65B |